The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder.

Older adults face unique mental health barriers, from misdiagnosis to stigma. This blog explores how we can improve care ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

Consider routine follow-up, especially after medication has been stopped Gabapentinoids, including gabapentin and pregabalin, are a class of drugs that have anticonvulsant, analgesic, and anxiolytic ...

Brittany Cartwright is defending her "honesty" about her apparently lackluster sex life with her estranged husband, Jax ...

A pioneering Nova Scotia program that provides patients with basic psychiatric diagnoses is winning praise for slashing wait ...

There is a difference between the terms "tardive dyskinesia" and "tardive syndrome" that clinicians should be aware of when providing care.

Discover Alkermes' Q1 2025 insights: impressive revenue growth, LYBALVI sales up 23%, and progress in the ALKS 2680 program.

Digital mood monitoring in people with bipolar disorder shows that sleep and activity changes precede hypomanic episodes by ...

The revival of Waterloo Road last year has proved a roaring success for the BBC, once again managing to captivate the youth ...